STOCK TITAN
  1. Home
  2. Sec-filings
  3. NUVL
  4. [4] – Pelish Henry E. (CIK 0002029477)

[4] – Pelish Henry E. (CIK 0002029477)

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Nuvalent (NUVL) insider activity: The Chief Scientific Officer reported option exercises and open‑market sales on 10/13/2025 and 10/14/2025 under a Rule 10b5-1 trading plan adopted on November 1, 2024.

Exercises included Class A Common Stock options for 1,669 at $18.93, 4,168 at $27.85, and 1,800 at $72.35 on 10/13, and 731 at $18.93, 877 at $27.85, and 825 at $29.33 on 10/14. Sales included 7,637 at a weighted average price of $89.81 on 10/13 (range $89.80–$89.83), and on 10/14: 1,167 at $84.98 (range $84.64–$85.63), 866 at $86.11 (range $85.89–$86.81), and 400 at $87.39 (range $87.33–$87.56).

Following the reported transactions, the reporting person beneficially owned 65,963 Class A Common Stock shares directly.

Nuvalent (NUVL) insider activity: Il Capo della Direzione Scientifica ha riportato esercizi di opzioni e vendite sul mercato aperto il 13/10/2025 e il 14/10/2025 nell'ambito di un piano di trading Rule 10b5-1 adottato il 1 novembre 2024.

Gli esercizi comprendevano opzioni di Class A Common Stock per 1.669 a 18,93 $, 4.168 a 27,85 $, e 1.800 a 72,35 $ il 13/10, e 731 a 18,93 $, 877 a 27,85 $, e 825 a 29,33 $ il 14/10. Le vendite includevano 7.637 ad un prezzo medio ponderato di 89,81 $ il 13/10 (intervallo 89,80–89,83 $) e il 14/10: 1.167 a 84,98 $ (intervallo 84,64–85,63 $), 866 a 86,11 $ (intervallo 85,89–86,81 $), e 400 a 87,39 $ (intervallo 87,33–87,56 $).

Dopo le transazioni riportate, la persona che riporta deteneva direttamente 65.963 azioni ordinarie di Classe A.

Actividad interna de Nuvalent (NUVL): El Director Científico reportó ejercicios de opciones y ventas en el mercado abierto el 13/10/2025 y el 14/10/2025 bajo un plan de trading Rule 10b5-1 aprobado el 1 de noviembre de 2024.

Los ejercicios incluyeron opciones de acciones comunes de Clase A por 1,669 a 18,93 $, 4,168 a 27,85 $ y 1,800 a 72,35 $ el 13/10, y 731 a 18,93 $, 877 a 27,85 $ y 825 a 29,33 $ el 14/10. Las ventas incluyeron 7,637 a un precio medio ponderado de 89,81 $ el 13/10 (rango 89,80–89,83 $) y el 14/10: 1,167 a 84,98 $ (rango 84,64–85,63 $), 866 a 86,11 $ (rango 85,89–86,81 $), y 400 a 87,39 $ (rango 87,33–87,56 $).

Tras las transacciones reportadas, la persona reportante poseía directamente 65,963 acciones ordinarias Clase A.

뉴발렌트(NUVL) 내부자 활동: 최고 과학 책임자는 2024년 11월 1일에 채택된 Rule 10b5-1 거래 계획에 따라 2025년 10월 13일과 2025년 10월 14일에 옵션 행사 및 공개 시장 매도를 보고했습니다.

행사에는 10/13일 18.93달러에 1,669주, 27.85달러에 4,168주, 72.35달러에 1,800주, 10/14일 18.93달러에 731주, 27.85달러에 877주, 29.33달러에 825주가 포함되며, 매도에는 10/13일 가중평균가 89.81달러로 7,637주, 10/14일 84.98달러에 1,167주, 86.11달러에 866주, 87.39달러에 400주가 포함됩니다(범위 89.80–89.83 달러, 84.64–85.63 달러, 85.89–86.81 달러, 87.33–87.56 달러).

보고된 거래 후, 보고자는 직접 65,963주 Class A 보통주를 보유했습니다.

Activité interne de Nuvalent (NUVL) : Le Directeur scientifique a rapporté des exercices d'options et des ventes sur le marché libre les 13/10/2025 et 14/10/2025 dans le cadre d'un plan de négociation Rule 10b5-1 adopté le 1er novembre 2024.

Les exercices comprenaient des options sur des actions ordinaires de classe A pour 1 669 à 18,93 $, 4 168 à 27,85 $, et 1 800 à 72,35 $ le 13/10, et 731 à 18,93 $, 877 à 27,85 $, et 825 à 29,33 $ le 14/10. Les ventes comprenaient 7 637 à un prix moyen pondéré de 89,81 $ le 13/10 (plage 89,80–89,83 $), et le 14/10 : 1 167 à 84,98 $ (plage 84,64–85,63 $), 866 à 86,11 $ (plage 85,89–86,81 $), et 400 à 87,39 $ (plage 87,33–87,56 $).

Suite aux transactions rapportées, la personne qui déclare détenait directement 65 963 actions ordinaires de Classe A.

Nuvalent (NUVL) Insider-Aktivitäten: Der Chief Scientific Officer meldete Optionsausübungen und Verkäufe am offenen Markt am 13.10.2025 und 14.10.2025 im Rahmen eines am 1. November 2024 angenommenen Rule 10b5-1-Handelsplans.

Zu den Ausübungen gehörten Optionen auf Class A Common Stock in Höhe von 1.669 zu 18,93 $, 4.168 zu 27,85 $ und 1.800 zu 72,35 $ am 13.10, sowie 731 zu 18,93 $, 877 zu 27,85 $ und 825 zu 29,33 $ am 14.10. Die Verkäufe umfassten 7.637 zu einem gewichteten Durchschnittspreis von 89,81 $ am 13.10 (Bandbreite 89,80–89,83 $) und am 14.10: 1.167 zu 84,98 $ (Bandbreite 84,64–85,63 $), 866 zu 86,11 $ (Bandbreite 85,89–86,81 $) und 400 zu 87,39 $ (Bandbreite 87,33–87,56 $).

Nach den gemeldeten Transaktionen besaß die meldende Person direkt 65.963 Class A Stammaktien.

نشاط الداخل لنوفالنت (NUVL): أبلغ كبير الضباط العلمي عن تمارين خيارات وبيع في السوق المفتوح في 13/10/2025 و14/10/2025 بموجب خطة التداول Rule 10b5-1 المعتمدة في 1 نوفمبر 2024.

شملت التمارين خيارات لسهم Class A Common Stock لـ 1,669 بسعر 18.93 دولار، و4,168 بسعر 27.85 دولار، و1,800 بسعر 72.35 دولار في 13/10، و731 بسعر 18.93 دولار، و877 بسعر 27.85 دولار، و825 بسعر 29.33 دولار في 14/10. شملت عمليات البيع 7,637 بسعر متوسط مرجح 89.81 دولار في 13/10 (النطاق 89.80–89.83 دولار)، وفي 14/10: 1,167 بسعر 84.98 دولار (النطاق 84.64–85.63 دولار)، و866 بسعر 86.11 دولار (النطاق 85.89–86.81 دولار)، و400 بسعر 87.39 دولار (النطاق 87.33–87.56 دولار).

بعد المعاملات المبلّغ عنها، امتلك الشخص المبلغ مباشرة 65,963 سهماً من Class A Common Stock.

Nuvalent (NUVL) 内部人活动： 首席科学官报告在 2025/10/13 和 2025/10/14 根据于 2024/11/01 通过的 Rule 10b5-1 交易计划进行期权行权和公开市场卖出。

行权包括 10/13 的 1,669 股 A 类普通股，价格 18.93 美元；4,168 股，27.85 美元；1,800 股，72.35 美元；以及 10/14 的 731 股，18.93 美元；877 股，27.85 美元；825 股，29.33 美元。卖出包括 10/13 的加权平均价 89.81 美元共 7,637 股，10/14 的 1,167 股 84.98 美元（区间 84.64–85.63 美元）、866 股 86.11 美元（区间 85.89–86.81 美元）、400 股 87.39 美元（区间 87.33–87.56 美元）。

在上述交易报告后，报告人直接持有 65,963 股 A 类普通股。

Positive
  • None.
Negative
  • None.

Insights

Analyzing...

Nuvalent (NUVL) insider activity: Il Capo della Direzione Scientifica ha riportato esercizi di opzioni e vendite sul mercato aperto il 13/10/2025 e il 14/10/2025 nell'ambito di un piano di trading Rule 10b5-1 adottato il 1 novembre 2024.

Gli esercizi comprendevano opzioni di Class A Common Stock per 1.669 a 18,93 $, 4.168 a 27,85 $, e 1.800 a 72,35 $ il 13/10, e 731 a 18,93 $, 877 a 27,85 $, e 825 a 29,33 $ il 14/10. Le vendite includevano 7.637 ad un prezzo medio ponderato di 89,81 $ il 13/10 (intervallo 89,80–89,83 $) e il 14/10: 1.167 a 84,98 $ (intervallo 84,64–85,63 $), 866 a 86,11 $ (intervallo 85,89–86,81 $), e 400 a 87,39 $ (intervallo 87,33–87,56 $).

Dopo le transazioni riportate, la persona che riporta deteneva direttamente 65.963 azioni ordinarie di Classe A.

Actividad interna de Nuvalent (NUVL): El Director Científico reportó ejercicios de opciones y ventas en el mercado abierto el 13/10/2025 y el 14/10/2025 bajo un plan de trading Rule 10b5-1 aprobado el 1 de noviembre de 2024.

Los ejercicios incluyeron opciones de acciones comunes de Clase A por 1,669 a 18,93 $, 4,168 a 27,85 $ y 1,800 a 72,35 $ el 13/10, y 731 a 18,93 $, 877 a 27,85 $ y 825 a 29,33 $ el 14/10. Las ventas incluyeron 7,637 a un precio medio ponderado de 89,81 $ el 13/10 (rango 89,80–89,83 $) y el 14/10: 1,167 a 84,98 $ (rango 84,64–85,63 $), 866 a 86,11 $ (rango 85,89–86,81 $), y 400 a 87,39 $ (rango 87,33–87,56 $).

Tras las transacciones reportadas, la persona reportante poseía directamente 65,963 acciones ordinarias Clase A.

뉴발렌트(NUVL) 내부자 활동: 최고 과학 책임자는 2024년 11월 1일에 채택된 Rule 10b5-1 거래 계획에 따라 2025년 10월 13일과 2025년 10월 14일에 옵션 행사 및 공개 시장 매도를 보고했습니다.

행사에는 10/13일 18.93달러에 1,669주, 27.85달러에 4,168주, 72.35달러에 1,800주, 10/14일 18.93달러에 731주, 27.85달러에 877주, 29.33달러에 825주가 포함되며, 매도에는 10/13일 가중평균가 89.81달러로 7,637주, 10/14일 84.98달러에 1,167주, 86.11달러에 866주, 87.39달러에 400주가 포함됩니다(범위 89.80–89.83 달러, 84.64–85.63 달러, 85.89–86.81 달러, 87.33–87.56 달러).

보고된 거래 후, 보고자는 직접 65,963주 Class A 보통주를 보유했습니다.

Activité interne de Nuvalent (NUVL) : Le Directeur scientifique a rapporté des exercices d'options et des ventes sur le marché libre les 13/10/2025 et 14/10/2025 dans le cadre d'un plan de négociation Rule 10b5-1 adopté le 1er novembre 2024.

Les exercices comprenaient des options sur des actions ordinaires de classe A pour 1 669 à 18,93 $, 4 168 à 27,85 $, et 1 800 à 72,35 $ le 13/10, et 731 à 18,93 $, 877 à 27,85 $, et 825 à 29,33 $ le 14/10. Les ventes comprenaient 7 637 à un prix moyen pondéré de 89,81 $ le 13/10 (plage 89,80–89,83 $), et le 14/10 : 1 167 à 84,98 $ (plage 84,64–85,63 $), 866 à 86,11 $ (plage 85,89–86,81 $), et 400 à 87,39 $ (plage 87,33–87,56 $).

Suite aux transactions rapportées, la personne qui déclare détenait directement 65 963 actions ordinaires de Classe A.

Nuvalent (NUVL) Insider-Aktivitäten: Der Chief Scientific Officer meldete Optionsausübungen und Verkäufe am offenen Markt am 13.10.2025 und 14.10.2025 im Rahmen eines am 1. November 2024 angenommenen Rule 10b5-1-Handelsplans.

Zu den Ausübungen gehörten Optionen auf Class A Common Stock in Höhe von 1.669 zu 18,93 $, 4.168 zu 27,85 $ und 1.800 zu 72,35 $ am 13.10, sowie 731 zu 18,93 $, 877 zu 27,85 $ und 825 zu 29,33 $ am 14.10. Die Verkäufe umfassten 7.637 zu einem gewichteten Durchschnittspreis von 89,81 $ am 13.10 (Bandbreite 89,80–89,83 $) und am 14.10: 1.167 zu 84,98 $ (Bandbreite 84,64–85,63 $), 866 zu 86,11 $ (Bandbreite 85,89–86,81 $) und 400 zu 87,39 $ (Bandbreite 87,33–87,56 $).

Nach den gemeldeten Transaktionen besaß die meldende Person direkt 65.963 Class A Stammaktien.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Pelish Henry E.
(Last) (First) (Middle)
C/O NUVALENT, INC.
ONE BROADWAY, 14TH FLOOR
(Street)
CAMBRIDGE MA 02142
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Nuvalent, Inc. [ NUVL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Scientific Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/13/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 10/13/2025 M(1) 1,669 A $18.93 67,632 D
Class A Common Stock 10/13/2025 M(1) 4,168 A $27.85 71,800 D
Class A Common Stock 10/13/2025 M(1) 1,800 A $72.35 73,600 D
Class A Common Stock 10/13/2025 S(1) 7,637 D $89.81(2) 65,963 D
Class A Common Stock 10/14/2025 M(1) 731 A $18.93 66,694 D
Class A Common Stock 10/14/2025 M(1) 877 A $27.85 67,571 D
Class A Common Stock 10/14/2025 M(1) 825 A $29.33 68,396 D
Class A Common Stock 10/14/2025 S(1) 1,167 D $84.98(3) 67,229 D
Class A Common Stock 10/14/2025 S(1) 866 D $86.11(4) 66,363 D
Class A Common Stock 10/14/2025 S(1) 400 D $87.39(5) 65,963 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $18.93 10/13/2025 M(1) 1,669 (6) 01/04/2032 Class A Common Stock 1,669 $0.00 14,968 D
Stock Option (Right to Buy) $27.85 10/13/2025 M(1) 4,168 (7) 01/06/2033 Class A Common Stock 4,168 $0.00 21,528 D
Stock Option (Right to Buy) $72.35 10/13/2025 M(1) 1,800 (8) 01/05/2034 Class A Common Stock 1,800 $0.00 27,100 D
Stock Option (Right to Buy) $18.93 10/14/2025 M(1) 731 (6) 01/04/2032 Class A Common Stock 731 $0.00 14,237 D
Stock Option (Right to Buy) $27.85 10/14/2025 M(1) 877 (7) 01/06/2033 Class A Common Stock 877 $0.00 20,651 D
Stock Option (Right to Buy) $29.33 10/14/2025 M(1) 825 (9) 03/01/2033 Class A Common Stock 825 $0.00 14,025 D
Explanation of Responses:
1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2024.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.80 to $89.83, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) of this Form 4.
3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.64 to $85.63, inclusive.
4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.89 to $86.81, inclusive.
5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.33 to $87.56, inclusive.
6. The shares underlying this option vest as follows: 25% of the shares vested on January 4, 2023, and the remainder have vested or shall vest over the three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
7. The shares underlying this option have vested or shall vest over the four years following January 6, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
8. The shares underlying this option have vested or shall vest over the four years following January 5, 2024 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
9. The shares underlying this option have vested or shall vest over the four years following March 1, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
/s/ Nathan N. McConarty, attorney-in-fact 10/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Nuvalent (NUVL) disclose in this Form 4?

The Chief Scientific Officer reported option exercises and open‑market sales of Class A Common Stock on 10/13/2025 and 10/14/2025 under a Rule 10b5-1 plan.

How many Nuvalent (NUVL) shares were sold and at what prices?

Sales were 7,637 shares at a weighted average $89.81 on 10/13, and on 10/14: 1,167 at $84.98, 866 at $86.11, and 400 at $87.39 (each with stated price ranges).

What options did the NUVL CSO exercise?

On 10/13: 1,669 at $18.93, 4,168 at $27.85, 1,800 at $72.35. On 10/14: 731 at $18.93, 877 at $27.85, 825 at $29.33.

Was the trading under a pre‑arranged plan?

Yes. Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on November 1, 2024.

What is the insider’s role at Nuvalent (NUVL)?

The reporting person is an Officer, serving as Chief Scientific Officer.

How many NUVL shares does the insider own after these trades?

Following the reported transactions, the insider beneficially owned 65,963 shares directly.
Stock NUVL logo
Nuvalent, Inc.

NASDAQ:NUVL

NUVL Rankings

#1211 Ranked by Market Cap
N/A Ranked by Dividends

NUVL Latest News

Oct 13, 2025
Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Sep 24, 2025
Nuvalent to Participate in the UBS 2025 Virtual Oncology Day
Sep 7, 2025
Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025
Aug 28, 2025
Nuvalent to Participate in the Cantor Global Healthcare Conference 2025
Aug 13, 2025
Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium

NUVL Latest SEC Filings

Oct 17, 2025
[Form 4] Nuvalent, Inc. Insider Trading Activity
Oct 17, 2025
[Form 4] Nuvalent, Inc. Insider Trading Activity
Oct 17, 2025
[Form 4] Nuvalent, Inc. Insider Trading Activity
Oct 17, 2025
[Form 4] Nuvalent, Inc. Insider Trading Activity
Oct 15, 2025
[4] – Balcom Alexandra (CIK 0001862147)

NUVL Stock Data

6.52B
63.38M
2.84%
109.13%
7.61%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE